Article Details
Retrieved on: 2018-02-05 23:45:00
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
<div>Now that Intellia Therapeutics $INTL is sailing steadily toward its first human studies with AbbVie vet John Leonard at the helm, Nessan Bermingham will officially re-join <b>Atlas Venture</b> as a venture partner. Bermingham had been CEO of the Atlas-backed CRISPR/Cas-9 upstart (which he co-founded) for ...</div>
Article found on:
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here